Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiping Fan

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
American Journal of Hematology|November 16, 2024
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph<sup>+</sup> acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort studyHui Liu, Hui Xu, Peiru Chi, et al.
Journal of Hepatology|October 29, 2022
Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosisBeiling Li, Changze Hong, Zhiping Fan, et al.
Biomarker Research|August 20, 2025
Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantationZhonghui Jiang, Ya Zhou, Yuxin Bai, et al.
BMJ Open|December 30, 2023
Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort studyLinjing Cai, Huan Chen, Yongqiang Wei, et al.
Transplantation|April 21, 2018
Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter StudyYonghua Li, Fengqi Duan, Haowen Xiao, et al.
The Lancet. Oncology|August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialLi Xuan, Yu Wang, Fen Huang, et al.
Blood Cancer Journal|February 19, 2025
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCTRongtao Xue, Min Dai, Erlie Jiang, et al.
The Lancet. Haematology|February 7, 2025
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trialSijian Yu, Fen Huang, Na Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|November 16, 2024
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph<sup>+</sup> acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort studyHui Liu, Hui Xu, Peiru Chi, et al.
Journal of Hepatology|October 29, 2022
Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosisBeiling Li, Changze Hong, Zhiping Fan, et al.
Biomarker Research|August 20, 2025
Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantationZhonghui Jiang, Ya Zhou, Yuxin Bai, et al.
BMJ Open|December 30, 2023
Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort studyLinjing Cai, Huan Chen, Yongqiang Wei, et al.
Transplantation|April 21, 2018
Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter StudyYonghua Li, Fengqi Duan, Haowen Xiao, et al.
The Lancet. Oncology|August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialLi Xuan, Yu Wang, Fen Huang, et al.
Blood Cancer Journal|February 19, 2025
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCTRongtao Xue, Min Dai, Erlie Jiang, et al.
The Lancet. Haematology|February 7, 2025
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trialSijian Yu, Fen Huang, Na Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Pageof 16